PMID- 18679038
OWN - NLM
STAT- MEDLINE
DCOM- 20081230
LR  - 20220318
IS  - 1423-0224 (Electronic)
IS  - 0302-282X (Linking)
VI  - 57
IP  - 4
DP  - 2008
TI  - Plasma brain-derived neurotrophic factor as a peripheral marker for the action 
      mechanism of antidepressants.
PG  - 194-9
LID - 10.1159/000149817 [doi]
AB  - Numerous studies have demonstrated that depression is associated with a decreased 
      expression of brain-derived neurotrophic factor (BDNF). BDNF shows 
      antidepressant-like effects in animal models. Therefore, we tested the hypothesis 
      that BDNF might be a peripheral marker for the mechanism of action of 
      antidepressant agents in humans. Thirty-two patients meeting the DSM-IV criteria 
      for major depressive disorder and 50 normal control subjects were recruited for 
      this study. Plasma BDNF levels and Hamilton Depression Rating Scales were 
      measured at baseline and 6 weeks after antidepressant administration. At 
      baseline, the mean plasma BDNF level was lower in the depressive patients (698.1 
      +/- 537.7 pg/ml) than in the control subjects (830.7 +/- 624.8 pg/ml), although 
      the difference was not statistically significant (p = 0.33). The plasma BDNF 
      levels in depressive patients significantly increased from 698.1 +/- 537.7 to 
      1,028.9 +/- 744.5 after 6 weeks of antidepressant treatment (p = 0.01). Moreover, 
      plasma BDNF levels were significantly increased after 6 weeks of treatment in the 
      responder group, while there was no statistically significant change in the 
      unresponsive group. These results suggest that the therapeutic response after 
      antidepressant administration might be attributable to the increase in BDNF 
      levels. BDNF may play a critical role in the action mechanism of antidepressant 
      drugs. Further studies with a larger number of subjects are needed to verify 
      these findings.
CI  - Copyright 2008 S. Karger AG, Basel.
FAU - Lee, Hwa-Young
AU  - Lee HY
AD  - Department of Psychiatry, College of Medicine, Korea University Anam Hospital, 
      Seoul, Korea.
FAU - Kim, Yong-Ku
AU  - Kim YK
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080805
PL  - Switzerland
TA  - Neuropsychobiology
JT  - Neuropsychobiology
JID - 7512895
RN  - 0 (Antidepressive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Cyclohexanols)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 41VRH5220H (Paroxetine)
RN  - 7D7RX5A8MO (Venlafaxine Hydrochloride)
SB  - IM
MH  - Adult
MH  - Antidepressive Agents/blood/*therapeutic use
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/blood/*drug effects
MH  - Case-Control Studies
MH  - Chi-Square Distribution
MH  - Citalopram/blood/therapeutic use
MH  - Cyclohexanols/blood/therapeutic use
MH  - Depressive Disorder, Major/*blood/drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Matched-Pair Analysis
MH  - Neuropsychological Tests
MH  - Paroxetine/blood/therapeutic use
MH  - Reference Values
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Venlafaxine Hydrochloride
EDAT- 2008/08/06 09:00
MHDA- 2008/12/31 09:00
CRDT- 2008/08/06 09:00
PHST- 2007/10/19 00:00 [received]
PHST- 2008/05/19 00:00 [accepted]
PHST- 2008/08/06 09:00 [pubmed]
PHST- 2008/12/31 09:00 [medline]
PHST- 2008/08/06 09:00 [entrez]
AID - 000149817 [pii]
AID - 10.1159/000149817 [doi]
PST - ppublish
SO  - Neuropsychobiology. 2008;57(4):194-9. doi: 10.1159/000149817. Epub 2008 Aug 5.